with Carl. patient momentum demand. driven growth by Thanks, physician happy continued the this our we quarter in very Slide XX, and VYVGART are both with consistent launch,
launch for six the are foundation first The of product. right building the in crucial the months
for team commitment strong to am incredibly of start. I to proud off So a demonstrated us the their getting
days, revenue were all drivers $XX each the still groups, While this quarter. stakeholder generated seeing we of in positive we early which we of million in signals in are the our are across key
currently in quarter. patients Japan six label from of some on first strong adds the time start I our was spend with have This therapy number which Let's the our We key translated within patients seronegative XX. therapy in of start. in patient with the from second had includes approximately broader new with very the overall, to and X,XXX pleased patients, globally, over launch. the Japan We the grateful initial with X,XXX including engage team And patients benefit to who Japan. week, Slide commercial we on are first weeks customers. contribution
true IVIg, is it this patients just Of treatment the types mestinon VYVGART, from Looking paradigm with at experience remained about patients, going multi-channel both or from who asking last quarter. have experience teams' the by was It other the a while about result steroids had empowering similar and early with engagement across to name. a XX% on X,XXX our the are approach have or of tremendous This XX% patients by other patients. for and the field physicians hoped also was VYVGART we outcome biologics.
adds, reason was we growth on patients see a forward. repeat one being terms VYVGART second balance but in of experience. quarter The of or have most more and extraordinary expect of other to new going biologic patients patient between that to The IVIg date
watching treatment closely in paradigm, are driver launch will because broad this we of the earlier whether We can important trajectory. gain adoption our an overall be
I to economic of VYVGART I potential gather. of share patients. health Before onto we move research the physicians, outcomes want to value gMG This proposition the reinforces some
accompanied when entering and were and by gathered ADAPT their approach of general life treatment. experienced the life, completing of data in anxiety issues mobility, the substantial usual population. following gMG study peak quality and quality majority ADAPT At improvement From daily self-care of health-related VYVGART the with patients patients depression. we reported discomfort, and the pain, of tasks. response, these the Often rapid early First, challenges into patients
on Overall, In placebo. know hospitalization hear a gMG we proposition Additionally, MG-related rewarding research it's significant treated burden impose patients. that patients XX% gMG aspect the lower to a very of ADAPT, of VYVGART this risk initial hospitalizations of experienced value patients. another showcasing to than VYVGART
deep and our on made antibody-driven. are as we we physicians, from resonating a on messages our awareness data science strategy the disease combined and increased driving of market of favorable mechanism driven. being and action strength ADAPT Moving the XX, with of commitment Slide and are on and is that This launch paying FcRn see our stay responses physicians to in With mechanism the the off safety profile. with of robust data the gMG physicians showing to
depth also breadth seeing adopters. prescribers, are early We in but physician from some
seeing One of of allocated on drivers are we the resources our targets. sales that top our is is the an to team priority breadth focused
upcoming XX% one quarters, going driving colleagues two with these And stage, to adoption goal At have physicians ahead this looking experience curve. their unknown big is early to our the Our of our written share scripts. is physicians and for that prescribers prescribing be to peers. or with
to launch use So initial a broader shifting be prescribers growth indicator these from going trajectory. key is to adoption and our
like work done being excellent I'd the market cover by access Finally, on Slide team that's to our XX.
payers X continue policies the constructive in VYVGART covering as have we achieved VYVGART and of have to majority approvals with conversations mestinon Patients been to a The months lives. XX these and XX% are have or access favorable at to commercial We specific covered of are steroids only we claims to last and aligned Medicare broad need committed published gain fail policies coverage. quarter typically for to label. time. and almost
some from to enrollment X prescribers July the expected, infusion which on will process a we give be conversion should more that and facilitate believe as effect confidence seamless straightforward. to into went J-code Our
the in Europe opinion The last Slide ready go of positive on receiving to launch global team to a Moving XX. month. our is after progress on CHMP
We month process Germany, we'll to reimbursement. and expect first a work prioritize the obtain we through revenues decision we can where among go and while next book
have France, Italy, including the Benelux, Europe We in UK. place also across and infrastructure commercial broad Spain,
support We filing Canada. Health in potential and with approval a Canada are building to infrastructure
at approval have Our geographies partner in filing in And to month. finally, and continue filed earlier for distributor place. this beyond Zai Lab look was we accepted other those we in arrangement the China
priorities same look though, unknowns launch It we on six empower days, In pleased saw stand sales partner last To in still rapid access. initial outlined drive this our months provide where We some I'm patient quarter in Slide after support, and our like. medicine. to strong we of adoption enable all XX, of really Israel fact, and across we still named-patient patients, with see launch. best-in-class are appropriate from already HCP conclude quarter signals early the through is
foundation us we yet so where are it's a product we still impact and and too that a play second say in soon do upon first And I are longer this. situation cycles, after First, still on how team to will primarily unique launched can patients built periods. build to strong individualized for has not our just understand dropout this. the we competitive over of rates have success with we five months or determined dosing know certainty out the and
patients and the satisfied We each therapy. but is are new Tim the number is benefit globally call from patients, us total be turn hard patients. conclude. would I'll with that there not what back This to with the a X,XXX driving about thinking of on behalf physicians out to of of working gMG now each day to engaging
